{"id":498,"date":"2026-09-06T21:48:45","date_gmt":"2026-09-06T21:48:45","guid":{"rendered":"https:\/\/premiumpeptide.shop\/research\/compounds\/retatrutid\/"},"modified":"2026-09-06T21:59:42","modified_gmt":"2026-09-06T21:59:42","slug":"retatrutid","status":"publish","type":"page","link":"https:\/\/premiumpeptide.shop\/en\/research\/compounds\/retatrutid\/","title":{"rendered":"Retatrutide"},"content":{"rendered":"

Retatrutide belongs to the group of long-chain acylated peptide analogues. Analytically it poses the same requirements as related conjugates, with the addition of an even closer proximity to blend formulations.<\/p>\n

What is retatrutide?<\/h2>\n

Retatrutide, also listed in the literature as LY3437943, is a synthetic peptide of 39 amino acids with a fatty acid side chain and an amidated C-terminus. The molecular mass lies in the range of approximately 4.7 kDa. It is described as an agonist at three related receptors from the incretin and glucagon family.<\/p>\n

As with other representatives of this class the molecule is amphiphilic in construction: a hydrophilic peptide backbone with a strongly lipophilic side chain.<\/p>\n

Research context<\/h2>\n

Retatrutide is the subject of published clinical and preclinical research. Compounds of this class listed in the catalogue are exclusively reference and research material and are not intended for use in humans or animals; this page makes no statements about effect, indication or application. Analytically significant is that retatrutide is traded on the market both as a single compound and in combination with other peptides. With combination products there is no single substance but a mixture, with a correspondingly different analytical question.<\/p>\n

Analytical identification<\/h2>\n